Ongoing Phase II Study and ECHELON-2 and ALCANZA Phase III Trials of Brentuximab Vedotin in CD30-Positive Mature T-Cell Lymphomas


Ongoing Phase II Study and ECHELON-2 and ALCANZA Phase III Trials of Brentuximab Vedotin in CD30-Positive Mature T-Cell Lymphomas
Slides from presentations at ICML 2013 and transcribed comments from recent interviews with Owen A O’Connor, MD, PhD (8/20/13) and Julie M Vose, MD, MBA (7/19/13)

O’Connor OA et al. ECHELON-2: Phase 3 trial of brentuximab vedotin and CHP versus CHOP in the frontline treatment of patients (Pts) with CD30+ mature T-cell lymphomas (MTCL). Proc ICML 2013;Abstract 138.

Oki Y et al. Safety and efficacy of brentuximab vedotin for treatment of relapsed or refractory mature T-/NK-cell lymphomas. Proc ICML 2013;Abstract 152.

Kim YH et al. Phase 3 study of brentuximab vedotin versus physician's choice of methotrexate or bexarotene in patients (Pts) with CD30-positive (CD30+) cutaneous T-cell lymphoma (CTCL). The ALCANZA study. Proc ICML 2013;Abstract 572.

Dr O’Connor is Professor of Medicine and Developmental Therapeutics and Director of the Center for Lymphoid Malignancies at Columbia University Medical Center in New York, New York.

Dr Vose is Neumann M and Mildred E Harris Professor, Chief of the Division of Hematology/Oncology and Professor of Medicine at Nebraska Medical Center in Omaha, Nebraska.